🇺🇸 Ciclesonide nasal in United States

11 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Vomiting — 2 reports (18.18%)
  2. Aortic Dissection — 1 report (9.09%)
  3. Arthralgia — 1 report (9.09%)
  4. Blood Pressure Increased — 1 report (9.09%)
  5. Bone Infarction — 1 report (9.09%)
  6. Condition Aggravated — 1 report (9.09%)
  7. Dehydration — 1 report (9.09%)
  8. Diarrhoea — 1 report (9.09%)
  9. Dizziness — 1 report (9.09%)
  10. Drug Effect Decreased — 1 report (9.09%)

Source database →

Other Allergy/Immunology approved in United States

Frequently asked questions

Is Ciclesonide nasal approved in United States?

Ciclesonide nasal does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Ciclesonide nasal in United States?

McGill University Health Centre/Research Institute of the McGill University Health Centre is the originator. The local marketing authorisation holder may differ — check the official source linked above.